Editorial: Cardiometabolic criteria matters in MASLD-Authors' reply.
作者信息
Tamaki Nobuharu, Kimura Takefumi, Wakabayashi Shun-Ichi, Umemura Takeji, Izumi Namiki, Loomba Rohit, Kurosaki Masayuki
机构信息
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Division of Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.
出版信息
Aliment Pharmacol Ther. 2024 Oct;60(8):1128-1129. doi: 10.1111/apt.18243. Epub 2024 Sep 3.
Abstract
摘要
相似文献
1
Editorial: Cardiometabolic criteria matters in MASLD-Authors' reply.社论：代谢性心血管疾病标准在代谢相关脂肪性肝病中的重要性——作者回复
Aliment Pharmacol Ther. 2024 Oct;60(8):1128-1129. doi: 10.1111/apt.18243. Epub 2024 Sep 3.
2
Editorial: Cardiometabolic criteria matters in MASLD.社论：心脏代谢标准在代谢相关脂肪性肝病中很重要。
Aliment Pharmacol Ther. 2024 Oct;60(8):1126-1127. doi: 10.1111/apt.18233. Epub 2024 Sep 3.
3
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
4
Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.代谢功能障碍相关脂肪性肝病的心血管代谢危险因素对死亡率的影响。
Nutr Metab Cardiovasc Dis. 2025 Jun;35(6):103965. doi: 10.1016/j.numecd.2025.103965. Epub 2025 Feb 26.
5
Long-term risk of irritable bowel syndrome associated with MASLD, MASLD type and different cardiometabolic risk factors: a large-scale prospective cohort study.与代谢功能障碍相关脂肪性肝病（MASLD）、MASLD类型及不同心血管代谢危险因素相关的肠易激综合征的长期风险：一项大规模前瞻性队列研究
BMC Gastroenterol. 2025 Aug 11;25(1):576. doi: 10.1186/s12876-025-04165-7.
6
Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.代谢相关脂肪性肝病患者中肝酶水平升高的患病率、比例及长期心代谢死亡率。
J Gastroenterol Hepatol. 2024 Sep;39(9):1939-1949. doi: 10.1111/jgh.16592. Epub 2024 May 9.
7
Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.代谢相关脂肪性肝病患者中 2 型糖尿病与心脏代谢结局。
Diabetes Res Clin Pract. 2024 May;211:111652. doi: 10.1016/j.diabres.2024.111652. Epub 2024 Apr 2.
8
Cardiovascular implications of MASLD: overview of the evidence.
Scand J Gastroenterol. 2025 Sep;60(9):910-918. doi: 10.1080/00365521.2025.2536585. Epub 2025 Jul 28.
9
Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease.代谢相关脂肪性肝病中心血管代谢相关预测指标及治疗靶点与肝脏相关事件和心血管事件的关系。
Aliment Pharmacol Ther. 2024 Oct;60(8):1033-1041. doi: 10.1111/apt.18205. Epub 2024 Aug 8.
10
Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study.心脏代谢指标与代谢功能障碍相关脂肪性肝病的发病及其向肝纤维化进展之间的关联：一项队列研究
Cardiovasc Diabetol. 2025 Apr 3;24(1):154. doi: 10.1186/s12933-025-02716-6.
本文引用的文献
1
Editorial: Cardiometabolic criteria matters in MASLD.社论：心脏代谢标准在代谢相关脂肪性肝病中很重要。
Aliment Pharmacol Ther. 2024 Oct;60(8):1126-1127. doi: 10.1111/apt.18233. Epub 2024 Sep 3.
2
Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease.代谢相关脂肪性肝病中心血管代谢相关预测指标及治疗靶点与肝脏相关事件和心血管事件的关系。
Aliment Pharmacol Ther. 2024 Oct;60(8):1033-1041. doi: 10.1111/apt.18205. Epub 2024 Aug 8.
3
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病中肝脏和心血管事件风险的血糖控制目标
Hepatol Res. 2024 Aug;54(8):753-762. doi: 10.1111/hepr.14025. Epub 2024 Feb 24.
4
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.非酒精性脂肪性肝病患者的 2 型糖尿病、肝功能失代偿和肝细胞癌：个体参与者水平数据荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):829-836. doi: 10.1016/S2468-1253(23)00157-7. Epub 2023 Jul 4.
5
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.非侵入性方法用于成像肝脂肪变性及其在非酒精性脂肪性肝病中的临床重要性。
Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0. Epub 2021 Nov 23.
6
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中肝纤维化状态与肝脏相关及心血管事件的风险差异
Clin Gastroenterol Hepatol. 2022 May;20(5):1171-1173.e2. doi: 10.1016/j.cgh.2021.07.021. Epub 2021 Jul 16.
7
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.代谢特征对非酒精性脂肪性肝病患者肝硬化和肝细胞癌风险的影响。
Hepatology. 2020 Mar;71(3):808-819. doi: 10.1002/hep.31014. Epub 2020 Feb 26.
8
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.磁共振质子密度脂肪分数与非酒精性脂肪性肝病患者纤维化进展相关。
Gastroenterology. 2018 Aug;155(2):307-310.e2. doi: 10.1053/j.gastro.2018.04.014. Epub 2018 Apr 13.
9
Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test.肝硬化患者糖尿病的诊断及临床意义：聚焦口服葡萄糖耐量试验
J Endocr Soc. 2017 May 23;1(7):886-896. doi: 10.1210/js.2017-00183. eCollection 2017 Jul 1.
Zotero 插件